We are monitoring the impact of COVID-19 on Europe Immunotherapy Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1094
Share on
Share on

Europe Immunotherapy Drugs Market Research Report – Segmented By Drug Type, Application & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, Growth & Forecast | 2019 - 2024

Pulished: February, 2020
ID: 1094
Pages: 145

Europe Immunotherapy Drugs Market Size & Growth (2019 – 2024):

As Per the Research Report, the Europe Immunotherapy Drugs Market Size is valued at USD 18.38 billion in 2019 and is forecasted to reach USD 30.41 billion by 2024, growing at a CAGR of 10.6% during the forecast period 2019-2024.

The usage of immunotherapy drugs is on the rise with the increases cases of cancer and autoimmune diseases. And also, owing to its lesser side effects, the market is likely to propel in the forecast period.

Immunotherapy is a way of treating cancer by enhancing the innate power of the immune system. The treatment involves using the individual’s own immune system to fight cancer cells. It either stimulates the function of each particular component of the immune system or acts against the signals caused by the cancer cells suppressing the responses by the immune system. These properties of the immunotherapy drugs to be able to aid the immune system fight against the abnormal cells make them being successfully used against diseases like infection, cancer, autoimmune and respiratory disorders.

Rising incidences of cancer and other autoimmune diseases have led to innovations in the development of drugs with the help of technological advancements. The other factors responsible for the growth of the market include emergence of biosimilars, higher efficacy than the common drugs with lower side effects and reduction in the overall time of developing and testing new drugs. However, the market is restrained by the higher cost related to the treatment and lower accessibility.

Europe Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories

  • By Drug Type: Monoclonal antibodies, Interferons, Interleukins, Vaccines, checkpoint inhibitors.
  • By Application: Blood Cancer, Cervical Cancer, Breast Cancer, Glioblastoma, Lung Cancer, Gastric Cancer, Prostate Cancer, Melanoma.
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe

Top Companies leading the Europe Immunotherapy Drugs Market Profiled in the Report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Drug Type                             

                                5.1.1 Monoclonal Antibodies     

                                5.1.2 Interferons             

                                5.1.3 Interleukins            

                                5.1.4 Vaccines  

                                5.1.5 Checkpoint Inhibitors         

                5.2 By Application                           

                                5.2.1 Blood Cancer         

                                5.2.2 Cervical Cancer     

                                5.2.3 Breast Cancer        

                                5.2.4 Glioblastoma         

                                5.2.5 Lung Cancer           

                                5.2.6 Gastric Cancer       

                                5.2.7 Prostate Cancer    

                                5.2.8 Melanoma              

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 Eli Lilly                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck                           

                9.3 Roche                           

                9.4 Amgen                         

                9.5 Novartis                       

                9.6 Celgene                       

                9.7 AstraZeneca               

                9.8 Bristol Myers Squibb                              

                9.9 GlaxoSmithKline PLC                              

                9.10 Seattle Genetics                    

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Immunotherapy Drugs Market By Region, From 2019-2024 (USD Billion)
  2. Europe Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  3. Europe Monoclonal Antibodies Market By Region, From 2019-2024 (USD Billion)
  4. Europe Interferons Market By Region, From 2019-2024 (USD Billion)
  5. Europe Interleukins Market By Region, From 2019-2024 (USD Billion)
  6. Europe Vaccines Market By Region, From 2019-2024 (USD Billion)
  7. Europe Checkpoint Inhibitors Market By Region, From 2019-2024 (USD Billion)
  8. Europe Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  9. Europe Blood Cancer Market By Region, From 2019-2024 (USD Billion)
  10. Europe Cervical Cancer Market By Region, From 2019-2024 (USD Billion)
  11. Europe Breast Cancer Market By Region, From 2019-2024 (USD Billion)
  12. Europe Glioblastoma Market By Region, From 2019-2024 (USD Billion)
  13. Europe Lung Cancer Market By Region, From 2019-2024 (USD Billion)
  14. Europe Gastric Cancer Market By Region, From 2019-2024 (USD Billion)
  15. Europe Prostate Cancer Market By Region, From 2019-2024 (USD Billion)
  16. Europe Melanoma Market By Region, From 2019-2024 (USD Billion)
  17. U.K Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  18. U.K Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  19. Spain Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  20. Spain Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  21. Germany Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  22. Germany Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  23. Italy Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  24. Italy Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  25. France Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  26. France Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample